GALT
GALECTIN THERAPEUTICS INC
Latest Form 4:Sale$83KbyJamil Khurram (Chief Medical Officer) · filed Jul 16, 2026
GALECTIN THERAPEUTICS INC (GALT) has 38 SEC Form 4 filings (134 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 4, 2026.
The most active filer is Chief Medical Officer Jamil Khurram with 11 filings. Insiders have net sold $521K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Joel Lewis
- Employees:15
- HQ:Norcross, GA, US
- IPO:2002-09-04
Insider Buying
$23K
reported purchases (SEC code P)
Insider Selling
$6.6M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$264.7M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 16,250 | $83K | Jul 16 | SEC ↗ | |
Shlevin Harold H.First in 6 months | Director | Sale | 7,732 | $39K | Jun 30 | SEC ↗ |
Shlevin Harold H.First in 6 months | Director | Sale | 22,268 | $112K | Jun 30 | SEC ↗ |
| Chief Medical Officer | Sale | 4,570 | $23K | Jun 30 | SEC ↗ | |
| Chief Medical Officer | Sale | 47,467 | $239K | Jun 30 | SEC ↗ | |
| Chief Medical Officer | Sale | 7,557 | $24K | Jun 25 | SEC ↗ | |
Jamil KhurramFirst in 5 months | Chief Medical Officer | Sale | 568 | $2K | May 28 | SEC ↗ |
| Director | Purchase | 300 | $810 | Feb 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 13,914 | $58K | Jan 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 25,732 | $100K | Jan 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 20,354 | $75K | Jan 6 | SEC ↗ | |
| President and CEO | Sale | 18,571 | $78K | Jan 6 | SEC ↗ | |
| President and CEO | Sale | 27,731 | $108K | Jan 6 | SEC ↗ | |
| President and CEO | Sale | 37,698 | $135K | Jan 6 | SEC ↗ | |
| Chief Medical Officer | Sale | 13,055 | $55K | Jan 6 | SEC ↗ | |
| Chief Medical Officer | Sale | 25,499 | $99K | Jan 6 | SEC ↗ | |
| Chief Medical Officer | Sale | 21,446 | $78K | Jan 6 | SEC ↗ | |
| Chief Medical Officer | Sale | 8,125 | $33K | Jan 5 | SEC ↗ | |
FREEMAN KEVIN DFirst filing | Director | Purchase | 5,500 | $20K | Dec 23 | SEC ↗ |
ELDRED KARYFirst filing | Director | Purchase | 700 | $3K | Dec 23 | SEC ↗ |
| Chief Medical Officer | Sale | 19,442 | $137K | Dec 19 | SEC ↗ | |
| Director | Sale | 24,499 | $172K | Dec 19 | SEC ↗ | |
| President and CEO | Sale | 7,829 | $55K | Dec 19 | SEC ↗ | |
| 10% Owner | Sale | 30,681 | $204K | Dec 18 | SEC ↗ | |
| Director | Sale | 19,793 | $124K | Dec 16 | SEC ↗ | |
| Director | Sale | 8,417 | $53K | Dec 16 | SEC ↗ | |
Shlevin Harold H.First filing | Insider | Sale | 139,000 | $831K | Dec 10 | SEC ↗ |
Shlevin Harold H.First filing | Insider | Sale | 16,790 | $105K | Dec 10 | SEC ↗ |
| 10% Owner | Sale | 30,000 | $164K | Dec 8 | SEC ↗ | |
| 10% Owner | Sale | 252,069 | $1.4M | Dec 8 | SEC ↗ | |
| Chief Financial Officer | Sale | 31,610 | $191K | Nov 19 | SEC ↗ | |
| Chief Financial Officer | Sale | 46,310 | $288K | Nov 19 | SEC ↗ | |
| President and CEO | Sale | 15,680 | $95K | Nov 19 | SEC ↗ | |
| President and CEO | Sale | 6,783 | $42K | Nov 19 | SEC ↗ | |
Jamil KhurramFirst filing | Chief Medical Officer | Sale | 79,617 | $436K | Nov 14 | SEC ↗ |
| Chief Financial Officer | Sale | 5,291 | $32K | Nov 12 | SEC ↗ | |
| President and CEO | Sale | 1,867 | $11K | Nov 12 | SEC ↗ | |
| 10% Owner | Sale | 40,000 | $210K | Nov 12 | SEC ↗ | |
| Chief Financial Officer | Sale | 200 | $1K | Nov 7 | SEC ↗ | |
| President and CEO | Sale | 200 | $1K | Nov 7 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,810 | $23K | Nov 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 28,629 | $174K | Nov 5 | SEC ↗ | |
| President and CEO | Sale | 1,300 | $8K | Nov 5 | SEC ↗ | |
| President and CEO | Sale | 14,420 | $88K | Nov 5 | SEC ↗ | |
10X Fund, L.P.First filing | 10% Owner | Sale | 50,000 | $247K | Oct 24 | SEC ↗ |
LEWIS JOELFirst filing | President and CEO | Sale | 14,000 | $89K | Sep 15 | SEC ↗ |
CALLICUTT JACK WFirst filing | Chief Financial Officer | Sale | 8,706 | $56K | Sep 15 | SEC ↗ |
Related companies
GALECTIN THERAPEUTICS INC is in the Healthcare sector.